# Efficacy, Safety and Tolerability of Ribavirin Monotherapy Followed by Combined Treatment With Ribavirin and Hydroxychloroquine in Patients Infected With Hepatitis C

> **NCT01833845** · PHASE1,PHASE2 · TERMINATED · sponsor: **BioLineRx, Ltd.** · enrollment: 4 (actual)

## Conditions studied

- Hepatitis C

## Interventions

- **DRUG:** Ribavirin
- **DRUG:** Hydroxychloroquine

## Key facts

- **NCT ID:** NCT01833845
- **Lead sponsor:** BioLineRx, Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2013-04
- **Primary completion:** 2014-04
- **Final completion:** 2014-04
- **Target enrollment:** 4 (ACTUAL)
- **Why stopped:** due to failure to recruit subjects
- **Last updated:** 2014-08-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01833845

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01833845, "Efficacy, Safety and Tolerability of Ribavirin Monotherapy Followed by Combined Treatment With Ribavirin and Hydroxychloroquine in Patients Infected With Hepatitis C". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01833845. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*